Company intelligence / Profile preview

Physip

Morioka-shi, Iwate, Japanphysiopt.com ↗

Ownership: Private
Development stage: Commercial

Overview

Physios Biotech develops advanced microphysiological systems ("organ-on-chip" devices) using nano/microfabrication to model human organ function for drug development, toxicity testing, and disease research. Their renal MPS enables functional studies of human kidney proximal tubule cells derived from iPSCs. They aim to reduce animal testing and improve predictive accuracy for human responses. No clinical results reported as they do not develop drugs directly but provide enabling technology.

Therapeutic areas: OtherOncologyNephrology
Modalities: DeviceMicrophysiological system (MPS) platform
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Simeox

Commercial

Indications: Bronchiectasis, Cystic fibrosis, Chronic obstructive pulmonary disease

Beyond the preview

Go deeper on Physip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Physip.

Explore the full profile